CRISPR-Cas9 is being used in clinical trials

​​ CRISPR-Cas9 has been implemented in a human clinical trial for the first time to lower LDL cholesterol and triglycerides. In a phase 1 trial, the gene editing technology is tested on individuals with lipid disorders to reduce and maintain lower LDL cholesterol and triglyceride levels in a safe manner. Those with the disorder that does not respond to medication were tested over a 60 day period in which their LDL and triglyceride levels were reduced by 50% within two weeks and were maintained over the 60 days. With no adverse effects related to the treatment and lasting maintenance of lower lipid levels, the trial has been considered a success.

Increased LDL cholesterol and triglyceride levels may lead to a heart attack or stroke over time and it is important to monitor those elevated counts. Those with lipid disorders are exposed to increased risk for cardiovascular issues. The efficiency and effectiveness of CRISPR-Cas9 in this clinical trial shows potential for further development in various avenues of human health. While CRISPR is still an emerging technology that is used experimentally, the initial results of its implementation have been promising. Although the gene editing tool is shrouded in ethical concern, its therapeutic ability provides a new window of potential applications. 

Source:

https://newsroom.clevelandclinic.org/2025/11/08/cleveland-clinic-first-in-human-trial-of-crispr-gene-editing-therapy-shown-to-safely-lower-cholesterol-and-triglycerides

Additional Link:

https://crisprtx.com/gene-editing